How do you manage a HR-/HER2+ breast cancer patient with local progression during neoadjuvant TCHP?
How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?
Community PollStarted
How would you treat a patient with HER2+ breast cancer who progresses on neoadjuvant TCHP?
64 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute and Emory University School of Medicine
Answered on
With the robust activity of HER2-targeted agents in the operable setting, this is a highly concerning clinical scenario. I would retest for HER2 on the biopsy specimen and confirm its positivity. Also, I have significantly limited the use of anthracyclines in patients with HER2+ breast cancer - give...
Join for free or sign in to see the full answer